Inhibiting BACE1 to reverse synaptic dysfunctions in Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Abstract
Over the past two decades, many studies have identified significant contributions of toxic β-amyloid peptides (Aβ) to the etiology of Alzheimer’s disease (AD), which is the most common age-dependent neurodegenerative disease. AD is also recognized as a disease of synaptic failure. Aβ, generated by sequential proteolytic cleavages of amyloid precursor protein (APP) by BACE1 and γ-secretase, is one of major culprits that cause this failure. In this review, we summarize current findings on how BACE1-cleaved APP products impact learning and memory through proteins localized on glutamatergic, GABAergic, and dopaminergic synapses. Considering the broad effects of Aβ on all three types of synapses, BACE1 inhibition emerges as a practical approach for ameliorating Aβ-mediated synaptic dysfunctions. Since BACE1 inhibitory drugs are currently in clinical trials, this review also discusses potential complications arising from BACE1 inhibition. We emphasize that the benefits of BACE1 inhibitory drugs will outweigh the concerns.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
AMPA Receptor Trafficking and Synaptic Plasticity
Malinow, R., & Malenka, R. C. (2002) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.25.112701.142758 · Cited by 2,588 · cited 1×
“Compared to relatively stationary NMDARs, trafficking of AMPARs to dendrites and spines is a key step for the control of postsynaptic plasticity; LTP promotes recruitment of more AMPAs to postsynaptic membranes for long-lasting potentials (Malinow and Malenka, 2002).”
The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes
Benilova, I., Karran, E., & De Strooper, B. (2012) · Nature Neuroscience · doi:10.1038/nn.3028 · Cited by 1,962 · cited 2×
“, 2009)] and the lack of patients diagnosed with amyloid plaque-only dementia (Benilova et al., 2012; Skaper, 2012), it is legitimate to question whether work on the Amyloid Cascade Hypothesis has reached an impasse.”
Plasticity during stroke recovery: from synapse to behaviour
Murphy, T. H., & Corbett, D. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2735 · Cited by 1,938 · cited 1×
“Enhanced synaptic transmission translates to stronger synaptic strength; memory formation is highly related to long-term changes in synaptic strength, which is quantifiable by electrophysiological measures (Murphy and Corbett, 2009).”
Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein
De Strooper, B., Saftig, P., Craessaerts, K., Vanderstichele, H., Guhde, G., Annaert, W., Von Figura, K., & Van Leuven, F. (1998) · Nature · doi:10.1038/34910 · Cited by 1,818 · cited 1×
“…et al., 1999; Lin et al., 2000; Sinha et al., 1999; Vassar et al., 1999; Yan et al., 1999). γ-secretase is a complex composed mainly of four transmembrane proteins: presenilin-1 or -2, nicastrin, Aph1, and Pen2 (De Strooper et al., 1998; Francis et al., 2002; Li et al., 2000; Yu et al., 2000).”
Dopamine neuron systems in the brain: An update
Björklund, A., & Dunnett, S. B. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.03.006 · Cited by 1,777 · cited 1×
“…(Ferando and Mody, 2014). iii) Dopaminergic synapses Dopaminergic synapses, formed by presynaptic axonal termini from dopaminergic neurons and dendrites from pyramidal neurons or interneurons, play a key role in protein synthesis-dependent forms of synaptic plasticity (Bjorklund and Dunnett, 2007).”
Palop, J. J., Chin, J., Roberson, E. D., Wang, J., Thwin, M. T., Bien-Ly, N., Yoo, J., Ho, K. O., Yu, G.-Q., Kreitzer, A., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.07.025 · Cited by 1,653 · cited 1×
“In AD PS1/APP J20 mouse dentate gyrus, aberrant overexcitation is linked to high levels of Aβ, which sensitizes at least some neuronal networks due to disrupted GABA function (Palop et al., 2007).”
Amyloid-β–induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks
Palop, J. J., & Mucke, L. (2010) · Nature Neuroscience · doi:10.1038/nn.2583 · Cited by 1,651 · cited 3×
“Reportedly, abnormal accumulation of Aβ in the form of dimers, trimers, or oligomers in the synaptic cleft is highly correlated with memory- related synaptic dysfunctions in AD (Haass and Selkoe, 2007; Palop and Mucke, 2010; Sheng et al., 2012).”
APP Processing and Synaptic Function
Kamenetz, F., Tomita, T., Hsieh, H., Seabrook, G., Borchelt, D., Iwatsubo, T., Sisodia, S., & Malinow, R. (2003) · Neuron · doi:10.1016/s0896-6273(03)00124-7 · Cited by 1,644 · cited 1×
“Suppressed Aβ generation by γ secretase inhibition is sufficient to increase EPSC frequency (Kamenetz et al., 2003).”
Shankar, G. M., Bloodgood, B. L., Townsend, M., Walsh, D. M., Selkoe, D. J., & Sabatini, B. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4970-06.2007 · Cited by 1,592 · cited 1×
“Aβ, mainly in soluble multimers or oligomers, directly interacts with NMDARs in pathophysiological conditions (Lacor et al., 2007; Shankar et al., 2007).”
Cited by
Jadiya, P., Kolmetzky, D. W., Tomar, D., Di Meco, A., Lombardi, A. A., Lambert, J. P., Luongo, T. S., Ludtmann, M. H., Praticò, D., & Elrod, J. W. (2019) · Nature Communications · doi:10.1038/s41467-019-11813-6 · Cited by 323
The BACE‐1 inhibitor CNP520 for prevention trials in Alzheimer's disease
Neumann, U., Ufer, M., Jacobson, L. H., Rouzade‐Dominguez, M., Huledal, G., Kolly, C., Lüönd, R. M., Machauer, R., Veenstra, S. J., Hurth, K., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201809316 · Cited by 177
“…compounds has emerged as a new concept for treatment of AD (Vassar et al, 2014; Eketjall et al, 2016; Kennedy et al, 2016; Timmers et al, 2016, 2017; Yan et al, 2016; Cebers et al, 2017) by preventing the generation and deposition of Ab rather than just treating the dementia symptoms.”
Background3D culture models of Alzheimer’s disease: a road map to a “cure-in-a-dish”
Choi, S. H., Kim, Y. H., Quinti, L., Tanzi, R. E., & Kim, D. Y. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0139-7 · Cited by 132
Kimura, A., Hata, S., & Suzuki, T. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.744722 · Cited by 95
Qu, J., Xiong, X., Hujie, G., Ren, J., Yan, L., & Ma, L. (2021) · Cell Cycle · doi:10.1080/15384101.2021.1982507 · Cited by 30
Metadata
- Authors
- Yan, R., Fan, Q., Zhou, J., & Vassar, R.
- Venue
- Neuroscience & Biobehavioral Reviews
- Publisher
- Elsevier BV
- Published
- 2016-06
- Volume
- 65
- Pages
- 326-340
- ISSN
- 0149-7634 (ISSN-L)
- OpenAlex
- W2317591111
- Cited by
- 71
- References
- 75
- FWCI
- 7.53
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhibiting BACE1 to reverse synaptic dysfunctions in Alzheimer’s disease. https://app.cochat.ai/papers/10.1016/j.neubiorev.2016.03.025
- The paper
- Yan, R., Fan, Q., Zhou, J., & Vassar, R. (2016). Inhibiting BACE1 to reverse synaptic dysfunctions in Alzheimer’s disease. Neuroscience & Biobehavioral Reviews. https://doi.org/10.1016/j.neubiorev.2016.03.025
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.